Molecular HIV Host Interactions Section
Maureen M. Goodenow, Ph.D.
Chief, Molecular HIV Host Interactions Section
Director, NIH Office of AIDS Research
Contact: For contact information, search the NIH Enterprise Directory.
Major Areas of Research
- Effect of recreational substance use, e.g., marijuana, tobacco products, and alcohol, on gene expression and biological pathways in youth with HIV (YWH) on antiretroviral therapy (ART).
- Transcriptome bioprofiles in HIV-exposed but uninfected (HEU) children in comparison to HIV-unexposed and uninfected (HUU) children.
- HIV-1 cell tropism, latency, reservoir, reactivation, and evolution of the HIV-1 genome over the course of infection with/without ART.
- Development and maturation of immunoglobulin repertoires, and response to vaccines in early human life.
Program Description
The major research focus of the Molecular HIV Host Interactions Section is to investigate interactions between HIV-1 and host, in particular children, adolescents, and young adults, at the molecular level, which includes the following:
- Effect of recreational substance use, e.g., marijuana, tobacco products, and alcohol, on gene expression and biological pathways in youth with HIV (YWH) on antiretroviral therapy (ART).
- Transcriptome bioprofiles in HIV-exposed but uninfected (HEU) children in comparison to HIV-unexposed and uninfected (HUU) children.
- HIV-1 cell tropism, latency, reservoir, reactivation, and evolution of the HIV-1 genome over the course of infection with/without ART.
- Development and maturation of immunoglobulin repertoires, and response to vaccines in early human life.
Biography
Education
Ph.D., Albert Einstein College of Medicine, The Bronx, NY
Dr. Goodenow received her undergraduate degree in biology from Fordham University and her Ph.D. in molecular genetics from the Albert Einstein College of Medicine. Following a postdoctoral fellowship in molecular oncology at the Sloan Kettering Institute, Dr. Goodenow was a visiting scientist at the Pasteur Institute in Paris, where she began her study of HIV.
Dr. Goodenow was a professor of pathology, immunology, and laboratory medicine at the University of Florida, Gainesville, where she held the Stephany W. Holloway University Endowed Chair for AIDS Research. She also was the Director of the Center for Research in Pediatric Immune Deficiency Diseases.
She served as the acting director of the Office for Research and Science in the U.S. Department of State, Office of the U.S. Global AIDS Coordinator, and Office of Global Health Diplomacy. Dr. Goodenow was the 2012 recipient of the prestigious Jefferson Science Fellowship at the State Department, where she served as senior science advisor in the Office of Economic Policy’s Bureau of East Asian and Pacific Affairs.
Dr. Goodenow was appointed Associate Director for HIV/AIDS Research at NIH, and Director of the NIH Office of AIDS Research in 2016, coordinating the HIV/AIDS research agenda across NIH. She also is chief of the Molecular HIV Host Interactions Section in NIAID.
Dr. Goodenow is the recipient of the Gertrude and Herman Silver 24th Annual Lecture Award and the Wistar Institute’s Jonathan Lax Memorial Award.
She continues to invest in the next generation of scientists and has trained more than 50 doctoral and postdoctoral fellows. A respected, peer-reviewed author, Dr. Goodenow has published more than 100 articles and book chapters, in addition to serving as a reviewer for more than 10 journals.
Selected Publications
Yin L, Dinasarapu AR, Borkar SA, Chang KF, De Paris K, Kim-Chang JJ, Sleasman JW, Goodenow MM. Anti-inflammatory effects of recreational marijuana in virally suppressed youth with HIV-1 are reversed by use of tobacco products in combination with marijuana. Retrovirology. 2022 May 31;19(1):10.
Yin L, Chang KF, Nakamura KJ, Kuhn L, Aldrovandi GM, Goodenow MM. Unique genotypic features of HIV-1 C gp41 membrane proximal external region variants during pregnancy relate to mother-to-child transmission via breastfeeding. J Clin Pediatr Neonatol. 2021;1(1):9-20.
Dybul M, Attoye T, Baptiste S, Cherutich P, Dabis F, Deeks SG, Dieffenbach C, Doehle B, Goodenow MM, Jiang A, Kemps D, Lewin SR, Lumpkin MM, Mathae L, McCune JM, Ndung'u T, Nsubuga M, Peay HL, Pottage J, Warren M, Sikazwe I; Sunnylands 2019 Working Group. The case for an HIV cure and how to get there. Lancet HIV. 2021 Jan;8(1):e51-e58.
Baloh CH, Borkar SA, Chang KF, Yao J, Hershfield MS, Parikh SH, Kohn DB, Goodenow MM, Sleasman JW, Yin L. Normal IgH Repertoire Diversity in an Infant with ADA Deficiency After Gene Therapy. J Clin Immunol. 2021 Oct;41(7):1597-1606.
Kim-Chang JJ, Wilson L, Chan C, Fischer B, Venturi G, Goodenow MM, Aldrovandi G, Weber TJ, Sleasman JW; Adolescent Medicine Trials Network for HIV/AIDS Interventions. Tenofovir Has Minimal Effect on Biomarkers of Bone Health in Youth with HIV Receiving Initial Antiretroviral Therapy. AIDS Res Hum Retroviruses. 2019 Aug;35(8):746-754.
Kim-Chang JJ, Donovan K, Loop MS, Hong S, Fischer B, Venturi G, Garvie PA, Kohn J, Rendina HJ, Woods SP, Goodenow MM, Nichols SL, Sleasman JW; Adolescent Medicine Trials Network for HIV/AIDS Interventions. Higher soluble CD14 levels are associated with lower visuospatial memory performance in youth with HIV. AIDS. 2019 Dec 1;33(15):2363-2374.
Research Group
MHHIS studies interactions between HIV-1 & human host, in particular children & young adults, to address the effect of recreational substance use on gene expression & biological pathways; immune perturbation in HIV-exposed but uninfected infants; response to vaccines in early life; & HIV-1 cell tropism, latency, reservoir, reactivation, & evolution over the course of infection with/without ART.